How does NordiDros P fit into a modern structured cycle plan?

NordiDros P is introduced as a peak-phase overlay within a periodised cycle, typically starting from week four or five after the base compound has established stable serum levels. Modern cycle design treats Drostanolone Propionate as an androgenic complement to the anabolic foundation — not a standalone compound — allowing it to act on a hormonal environment already primed by the primary compound.

At what point in a cycle should you start NordiDros P for best protocol results?

Coach-recommended frameworks consistently place NordiDros P entry at weeks four to five of a standard 12–16 week cycle. Beginning after the base compound's serum levels have stabilised — typically confirmed by subjective response indicators around week three — allows Drostanolone Propionate to amplify an already-active androgenic environment rather than compete with the establishment phase of longer-estered compounds.

How long does a modern Drostanolone Propionate cycle typically run?

Most structured modern protocols run NordiDros P for eight to twelve weeks within an overall cycle of ten to sixteen weeks. The propionate ester's short active window suits cycles with defined exit points, and the 10ml vial at 150mg/ml contains enough product to sustain a full ten-week run at 300mg per week without requiring an additional vial, which simplifies logistics planning considerably.

Can insulin syringes be used to dose NordiDros P at 150mg/ml, and what volumes are involved?

Yes — at 150mg/ml, a 100mg dose draws to exactly 0.67ml and a 75mg dose to 0.5ml, both within the practical range of a 1ml luer-lock syringe. Insulin-barrel syringes are technically compatible with these volumes, though standard 1ml syringes with a detachable needle are more commonly used for intramuscular administration. The concentrated formula keeps per-injection volumes low even at higher doses.

How should NordiDros P be stored after the vial has been opened?

Once punctured, NordiDros P should be stored at room temperature between 15°C and 25°C, away from direct light and heat sources; refrigeration is not required and may increase oil viscosity, making draws more difficult. The multi-dose vial's rubber stopper is designed for repeated sterile access — use a new needle for each draw to maintain the sterile barrier, and discard any unused content within 28 days of first puncture. (2) angle_used

Coach Recommended

Nordi Pharma

NordiDros P 150mg/ml 10ml Vial by Nordi Pharma

Name: NordiDros P 150mg/ml 10ml Vial by Nordi Pharma
Brand: Nordi Pharma
SKU: INJ-DROP-NOR-150-014
Price: 50.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

NordiDros P is a professionally formulated injectable androgenic compound delivering Drostanolone Propionate at 150mg per millilitre in a 10ml multi-dose vial, engineered specifically for structured integration into modern cycle blueprints where phase timing and compound sequencing are the primary design criteria. At 150mg/ml, each injection delivers a higher milligram yield per draw than standard 100mg/ml alternatives, reducing total injection volume without sacrificing dose precision — a practical advantage when cycle architects are managing multiple concurrent compounds. Batch release at Nordi Pharma is conditional on three documented checkpoints: HPLC potency confirmation, LAL endotoxin testing, and sterility assessment — each logged against the production lot before the vial leaves the facility.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers 150mg of Drostanolone Propionate per millilitre — the highest concentration format in the Nordi Pharma Drostanolone line, reducing injection volume per dose.
Designed for phased cycle entry from week four onward, aligning with modern periodised protocol frameworks.
Supports every-other-day injection scheduling without demanding excessive vial access — one 10ml vial covers a full ten-week phase.
Contributes to a refined hormonal environment during peak training phases by acting on free androgen availability within the cycle's established base.
Short ester structure allows clean, predictable cycle exits without extended washout periods disrupting transition timing.
HPLC-verified concentration ensures the declared 150mg/ml matches the actual dose drawn at each injection point.
Coach Recommended positioning reflects alignment with structured cycle frameworks used by experienced practitioners and competition-prep coaches.

Phase	Dosage	Note
Cycle Entry (Weeks 1–3)	Base compound only — NordiDros P not yet introduced	Allow the primary compound to establish stable serum levels before adding NordiDros P; do not begin Drostanolone Propionate simultaneously with longer-estered base compounds
Peak Phase Introduction (Weeks 4–8)	150–300mg per week (100mg EOD or 75mg EOD)	At 150mg/ml, 100mg draws to 0.67ml per injection; introduce at the lower end and assess androgenic response before escalating to 300mg weekly
Sustained Peak Phase (Weeks 8–12)	300mg per week (100mg EOD, 3 injections weekly)	Maintain consistent EOD schedule; align injection days with training sessions where possible; monitor subjective hardening response and adjust by 50mg weekly increments if needed
Cycle Exit (Final 1–2 Weeks)	Taper to 150mg per week or continue at 300mg then cease	The propionate ester clears within days of the final injection; schedule last injection to align with your planned PCT or transition window — coach-recommended frameworks suggest 3–5 days before PCT initiation

Key takeaways

Introduce NordiDros P at weeks four to five of your cycle for phased protocol precision.
Schedule every-other-day injections to match the propionate ester's active window.
Leverage 150mg/ml concentration to minimise injection volume across a full cycle.
Verify lot-specific HPLC and LAL results before integrating into a multi-compound stack.
Plan cycle exit using the short propionate clearance window for clean transition timing.

NordiDros P as a Modern Cycle Building Block

NordiDros P is a structured-cycle injectable defined by its role as a precision androgenic component — Drostanolone Propionate at 150mg/ml — designed to slot into periodised training and compound protocols rather than operate in isolation. Modern cycle architecture distinguishes between foundation phases, peak phases, and transition phases; NordiDros P is most commonly introduced in the peak and pre-competition phases, where its androgenic properties align with the dietary and training environment already in place. Drostanolone Propionate occupies the hardening and hormonal environment role within a multi-compound sequence, contributing to free androgen availability while keeping total weekly milligram load manageable.

Phase-Based Integration: Where NordiDros P Fits

A structured modern cycle typically runs 10–16 weeks in total, with Drostanolone Propionate introduced from week four or five onward — once the base compound has established a stable serum presence. This sequenced entry is deliberately later than a testosterone or nandrolone foundation: the rationale, supported by practitioner experience and athlete self-reported data across competitive bodybuilding communities, is that adding an androgenic overlay before the anabolic base is established produces less measurable benefit than layering it on top of an already-active hormonal environment. Compared to earlier-entry protocols where all compounds begin simultaneously on day one, phased introduction of NordiDros P from week four consistently appears in coach-recommended frameworks as the preferred timing model.

Injection Frequency and Weekly Scheduling

NordiDros P supports an every-other-day injection schedule driven by the short active window of the propionate ester, which pharmacokinetic literature documents at approximately two to three days. A standard weekly framework at 300mg total distributes across three injections per week of 100mg each (drawing 0.67ml per injection at 150mg/ml), fitting cleanly into structured training weeks where injection days align with training sessions. The 10ml vial volume sustains a full 10-week protocol at this dose within a single container, reducing the number of vial transitions a cycle requires.

Manufacturing Accountability

Nordi Pharma applies HPLC identity and potency assay, LAL endotoxin evaluation, and sterility testing as sequential release criteria for NordiDros P; each result is recorded against the specific production lot number and must satisfy pre-approved specification limits before dispatch. GMP-compliant production conditions govern the sterile compounding environment throughout. This three-checkpoint release model means the 150mg/ml concentration on the label corresponds to independently verified analytical measurement rather than API documentation alone.

Usage

Map NordiDros P into your cycle blueprint before the cycle begins — identify the start week (week four or five recommended by coach-based protocols), the weekly milligram target, and the planned final injection date relative to your PCT start.
Confirm your weekly dose and per-injection volume using the 150mg/ml concentration: 100mg = 0.67ml, 75mg = 0.5ml, 150mg = 1.0ml — calculate this in advance and note it on your cycle log.
Draw each dose with a fresh sterile needle through the rubber stopper; swab the stopper with an isopropyl alcohol wipe before each access to maintain the multi-dose vial's sterile integrity.
Administer intramuscularly into a large muscle group — glute, vastus lateralis, or deltoid — rotating sites on each injection day to prevent localised irritation from repeated access.
Follow your pre-established EOD schedule strictly; if a scheduled injection day is missed, do not double-dose on the following day — resume the regular schedule and log the gap in your cycle tracker.
At cycle end, log the date and dose of your final NordiDros P injection and count forward to your PCT initiation date based on the propionate ester's documented clearance window.

Warnings

Contraindications: NordiDros P is contraindicated in individuals with confirmed androgen sensitivity disorders, active prostate pathology, breast tissue malignancy in males, or severe hepatic or cardiovascular impairment. Not indicated for use in women due to virilisation risk associated with androgenic compounds at these concentrations. Individuals under 21 should not use this product as endogenous hormonal systems remain in development.

Side Effects: Androgenic side effects including accelerated scalp hair thinning in genetically predisposed individuals, increased sebum production, and potential acne flare-ups are reported with Drostanolone Propionate use. Suppression of endogenous testosterone production occurs with all exogenous androgens regardless of ester. Haematological changes — including elevated haematocrit — have been documented with anabolic androgenic steroid use and require periodic blood monitoring.

Monitoring: Obtain a full blood panel including total testosterone, LH, FSH, haematocrit, lipid profile (HDL/LDL), and liver enzymes at baseline before cycle initiation. Mid-cycle bloods at weeks six to eight allow identification of adverse shifts before cycle completion. Blood pressure should be self-monitored weekly throughout the cycle; escalating readings warrant dose reassessment.

PCT: Post-cycle therapy is required following NordiDros P use to support recovery of the hypothalamic-pituitary-gonadal axis. The propionate ester's short clearance timeline permits PCT initiation within approximately five to seven days of the final injection. Standard PCT frameworks incorporate SERMs such as Nolvadex or Clomid for four to six weeks; duration and dosing should reflect cycle length and total androgenic load used.

Frequently asked questions

How does NordiDros P fit into a modern structured cycle plan?: NordiDros P is introduced as a peak-phase overlay within a periodised cycle, typically starting from week four or five after the base compound has established stable serum levels. Modern cycle design treats Drostanolone Propionate as an androgenic complement to the anabolic foundation — not a standalone compound — allowing it to act on a hormonal environment already primed by the primary compound.
At what point in a cycle should you start NordiDros P for best protocol results?: Coach-recommended frameworks consistently place NordiDros P entry at weeks four to five of a standard 12–16 week cycle. Beginning after the base compound's serum levels have stabilised — typically confirmed by subjective response indicators around week three — allows Drostanolone Propionate to amplify an already-active androgenic environment rather than compete with the establishment phase of longer-estered compounds.
How long does a modern Drostanolone Propionate cycle typically run?: Most structured modern protocols run NordiDros P for eight to twelve weeks within an overall cycle of ten to sixteen weeks. The propionate ester's short active window suits cycles with defined exit points, and the 10ml vial at 150mg/ml contains enough product to sustain a full ten-week run at 300mg per week without requiring an additional vial, which simplifies logistics planning considerably.
Can insulin syringes be used to dose NordiDros P at 150mg/ml, and what volumes are involved?: Yes — at 150mg/ml, a 100mg dose draws to exactly 0.67ml and a 75mg dose to 0.5ml, both within the practical range of a 1ml luer-lock syringe. Insulin-barrel syringes are technically compatible with these volumes, though standard 1ml syringes with a detachable needle are more commonly used for intramuscular administration. The concentrated formula keeps per-injection volumes low even at higher doses.
How should NordiDros P be stored after the vial has been opened?: Once punctured, NordiDros P should be stored at room temperature between 15°C and 25°C, away from direct light and heat sources; refrigeration is not required and may increase oil viscosity, making draws more difficult. The multi-dose vial's rubber stopper is designed for repeated sterile access — use a new needle for each draw to maintain the sterile barrier, and discard any unused content within 28 days of first puncture. (2) angle_used

Manufacturer

Nordi Pharma's product line architecture for the NordiDros range reflects a deliberate specialisation strategy: rather than producing a single Drostanolone Propionate format and extending it uniformly, the brand has built its injectable portfolio around concentration tiers that serve distinct protocol roles. NordiDros P at 150mg/ml sits at the top of the Drostanolone concentration range, positioned specifically for experienced athletes constructing peak-phase and contest-preparation protocols where dose precision and volume efficiency both matter. The broader Nordi Pharma catalogue follows a consistent structural logic — each product within a compound class occupies a defined concentration tier with documented manufacturing parameters, meaning athletes building multi-compound cycles can select across the portfolio with confidence that concentration claims are analytically verified. HPLC potency confirmation, LAL endotoxin assay, and sterility testing are applied as sequential release gates across the NordiDros P production process, with results archived by lot number.

Product details

Brand	Nordi Pharma
Active ingredient	drostanolone propionate
Also known as	Masteron, Drolban, Drostanolone Propionate, NordiDros P, Nordi Pharma Masteron
Strength	150 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROP-NOR-150-014

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starscenturionVerified purchaseJul 18, 2026
Absolute game changer
Running this at 300mg/week alongside test e for 12 weeks. Strength shot up week 3, no water retention at all, physique looked dryer than anything I've run before. Pip was minimal, oil went in smooth. Bloods at week 8 showed hematocrit sitting at 47% which is fine. Would run again without hesitation.
Rating: 4 out of 5 starsbull_42Verified purchaseJun 1, 2026
Solid but pricey
good product, no complaints on quality. Dropped a fair bit of body fat over 10 weeks at 300mg/week and kept all my sterngth. Only gripe is the price point, bit steep compared to some alternatives. Still, quality feels legit so probably worth it. Joints were buzzing throughout which surprised me.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Masteron is an oil-based injectable solution delivering Drostanolone Propionate at 100mg/ml, distinguished by its capacity to bypass hepatic first-pass metabolism entirely — a pharmacokinetic advantage that oral androgen compounds cannot replicate. Each 10ml multi-dose vial provides a full cycle's supply of pharmaceutical-grade active, with systemic absorption occurring directly through intramuscular tissue into the bloodstream. Quality assurance is built into every lot: HPLC potency verification, LAL endotoxin screening, and GMP-certified filling suites are standard — not optional — at Beligas Pharmaceuticals.

€46.00

Masten-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Masten-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-100 is a fast-acting injectable androgenic compound delivering Drostanolone Propionate at 100mg/ml in single-dose 1ml ampoules, specifically engineered for rapid tissue uptake and measurable efficacy within the first days of administration. The propionate ester's short carbon chain enables peak plasma concentrations to establish quickly — typically within 24–48 hours of the first injection — making it one of the fastest-onset drostanolone formulations available. Every lot is released only after HPLC potency confirmation and LAL endotoxin screening; sterility is assured via Ph. Eur. 2.6.1-compliant testing conducted at BM Pharmaceuticals' GMP-certified facility.

€47.00

High Concentration

MasterTrex 150mg/ml 10ml Vial by Concentrex Labs

MasterTrex is a high-concentration Drostanolone Propionate injectable, formulated at 150 mg/ml in a 10 ml multi-dose vial and engineered for athletes who demand precise, schedule-driven injection timing across their cutting or pre-contest phase. At 150 mg/ml, each draw delivers a clinically meaningful dose in a compact volume, making every-other-day or every-third-day scheduling straightforward without excess injection site load. Quality is locked in at batch level: HPLC-quantified potency verification and LAL endotoxin testing are completed before any MasterTrex vial leaves the Concentrex Labs facility.

€50.00

Brand Quality

Masteron 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 100 is a drostanolone propionate injectable solution at 100mg/ml in a 10ml multi-dose vial, specifically suited to frontloading protocols that compress the time-to-steady-state window at the opening of a cycle. Because the propionate ester releases active drostanolone within a short half-life of approximately 2–3 days, calculated loading doses can bring circulating androgen levels to the target therapeutic range within the first 72 hours rather than waiting the usual week or more. Dragon-Pharma batch-releases every vial only after HPLC potency verification and LAL endotoxin clearance — two independent quality gates applied sequentially before product leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00